However, when we performed a similar analysis in 1002 patients with lung adenocarcinomas in the same cohort who were tested for anaplastic lymphoma kinase (ALK) rearrangements, ALK rearrangements were detected in 6.4% (64 of 1002) of lung adenocarcinomas and ALK rearrangements were significantly associated with advanced stage disease (OR, 3.78; 95% CI, 1.92–7.43; P < 0.001) in multivariable analysis incorporating age, sex, smoking status, and screening (S2 Table and S2 Fig), findings consistent with previous studies [34, 35]. The gene discussed is ALK; the disease is lung adenocarcinoma.